<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(1)</volume><submitter>Thomas S</submitter><funding>National Institute for Health Research (NIHR)</funding><funding>Rosetrees</funding><journal>Journal for immunotherapy of cancer</journal><pagination>214</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6689178</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.</pubmed_title><pmcid>PMC6689178</pmcid><funding_grant_id>M236-F1-CD1</funding_grant_id><funding_grant_id>NF-SI-0515-10101</funding_grant_id><pubmed_authors>Kaufman HL</pubmed_authors><pubmed_authors>Mansfield D</pubmed_authors><pubmed_authors>Bommareddy PK</pubmed_authors><pubmed_authors>Thomas S</pubmed_authors><pubmed_authors>Kyula JN</pubmed_authors><pubmed_authors>Smith H</pubmed_authors><pubmed_authors>Roulstone V</pubmed_authors><pubmed_authors>Kuncheria L</pubmed_authors><pubmed_authors>Harrington KJ</pubmed_authors><pubmed_authors>Coffin RS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.</name><description/><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Aug</publication><modification>2026-05-02T20:01:41.007Z</modification><creation>2025-02-19T01:34:46.979Z</creation></dates><accession>S-EPMC6689178</accession><cross_references><pubmed>31399043</pubmed><doi>10.1186/s40425-019-0682-1</doi></cross_references></HashMap>